TY - JOUR
T1 - Pharmacogenomics of cetuximab in metastatic colorectal carcinoma
AU - Russo, Antonio
AU - Giampieri, Riccardo
AU - Loupakis, Fotious
AU - Lorusso, Vito
AU - Cascinu, Stefano
AU - Brunetti, Anna Elisabetta
AU - Dell'Aquila, Emanuela
AU - Scartozzi, Mario
AU - Vincenzi, Bruno
AU - Silvestris, Nicola
AU - Falcone, Alfredo
AU - Tonini, Giuseppe
AU - Santini, Daniele
AU - Santini, Daniele
PY - 2014
Y1 - 2014
N2 - Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.
AB - Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.
UR - http://hdl.handle.net/10447/295558
UR - http://www.futuremedicine.com/loi/pgs?cookieSet=1
M3 - Article
VL - 15
SP - 1701
EP - 1715
JO - Pharmacogenomics
JF - Pharmacogenomics
SN - 1462-2416
ER -